Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma
Clinical trial NCT01462773 · COMPLETED
Trial details
- NCT number
- NCT01462773
- Sponsor
- Ohio State University Comprehensive Cancer Center
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2006-01-01
- Primary completion
- 2010-10-01
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.